Clinical Trial Update: Exploration of Fenestration Decompression Combined With Dalafenib in the Treatment of BRAF Mutant Ameloblastoma [Phase 3]

View source ↗

Summary

A Phase 3 trial exploring fenestration decompression combined with dalafenib for BRAF-mutant ameloblastoma is in unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ameloblastoma

Drugs mentioned

• dalafenib (dalafenib)

Snippet

Sponsor: Shandong University | Conditions: Ameloblastoma | Phase 3 | Status: UNKNOWN